Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05232032 · ClinicalTrials.gov registry record · Phase 2
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
A Phase 2 study of Depressive Disorder, Major and Anxiety Disorder, sponsored by Mclean Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT05232032 is a Phase 2 study of Depressive Disorder, Major and Anxiety Disorder that is actively recruiting participants, run by Mclean Hospital. The registered enrollment target is 112 participants, below the 240-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05232032, a Phase 2 study of Depressive Disorder, Major and Anxiety Disorder, is actively recruiting participants, sponsored by Mclean Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulation within (1) corticostriatal-midbrain circuitry and (2) nociceptin/orphanin FQ peptide and the nociceptin receptor (NOPR).
Conditions Studied
Interventions
- DEVICE Aversive stimuli
- DRUG Nociceptin Receptor Antagonist
Study Locations (1)
Massachusetts
- Mclean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05232032
The ClinicalTrials.gov registry entry for NCT05232032 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 240-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (53% lower). The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depressive Disorder, Major appearing as the primary indexed condition, and to 2 interventions - of which Aversive stimuli is the first listed.
NCT05232032 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05232032 about?
NCT05232032 is a clinical study titled "Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation". The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulati...
What is the current status of trial NCT05232032?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2025-02-01. Estimated completion is 2026-03-31.
What conditions does trial NCT05232032 study?
This clinical trial studies the following conditions: Depressive Disorder, Major, Anxiety Disorder.
What interventions are being tested in trial NCT05232032?
The interventions under investigation include: Aversive stimuli (DEVICE), Nociceptin Receptor Antagonist (DRUG).
Who is sponsoring clinical trial NCT05232032?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05232032 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
RECRUITING · Phase 2
-
Individualized Functional Connectivity Targeting in aiTBS for Depression
ACTIVE NOT RECRUITING · Phase 2
-
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
COMPLETED · Phase 2
-
A Safety, Efficacy and Tolerability Study of SEP-225289
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.